Compare Enveric Biosciences Inc (ENVB) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs MGM Resorts International — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while MGM Resorts International trades at $46.66 (market cap $11.98B). The key difference: MGM Resorts International is far larger — about 2251.9× Enveric Biosciences Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | MGM | |
|---|---|---|
Market Cap | $5.32M | $11.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $50.69 |
52-Week Low | $1.28 | $30.72 |
Enterprise Value | $408.82K | $41.03B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
MGM Resorts International (MGM) trades at $46.73, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $48.93. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 2026 missing slightly. The company maintains stable revenue around $17.5 billion but faces declining net profit margins, now at 1.03%. Acquisition interest from Barry Diller at $48.30 per share dominates recent news, potentially driving near-term volatility.
MGM offers moderate upside to the consensus target, supported by takeover speculation and solid cash flow, but high P/E of 64.16 and weak profitability metrics pose valuation risks. Investors should weigh acquisition prospects against fundamental challenges like debt levels and margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
